IBJNews

Lilly sues to block generic of Adcirca lung treatment

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly and Co., maker of the antipsychotic Zyprexa and impotence pill Cialis, sued Dutch drugmaker Synthon BV’s U.S. unit to prevent it from selling a generic version of the lung treatment Adcirca in the U.S.

Synthon Pharmaceuticals is seeking U.S. Food and Drug Administration approval to sell a copy of the medicine. Lilly and its Icos unit contend the copy would infringe two patents that expire in 2020.

Adcirca was approved in May to improve exercise ability in people with pulmonary arterial hypertension, a potentially deadly lung disorder that can cause shortness of breath, chest pain and eventually heart failure.

The medicine is a once-a-day tablet that contains the same active ingredient, tadalafil, as Cialis. The impotence pill was Lilly’s fifth-biggest drug last year with global sales of $1.56 billion, according to the company’s annual report.

The federal court complaint, filed March 15 in Lilly’s hometown of Indianapolis, seeks a court order that FDA approval can’t be granted before the patent expires.

Officials with Synthon in the Netherlands couldn’t immediately be reached for comment.

ADVERTISEMENT

  • ADCIRCA
    I NEED TO WRITE A LETTER OF FINANCIAL NEED FOR ADCIRCA. I HAVE PULMONARY HYPERTENSION.
    PLEASE ADVISE TO WHOM I SHOULD WRITE AND WHERE TO SEND MY LETTER.

    SINCERELY,

    SUSANNE LOVELL

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
ADVERTISEMENT